Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Immuno-Oncology Drugs Market Projected to Reach US$ 185.69 Billion by 2035 | Astute Analytica

globenewswire.com
VRTX Vertex's USD 4.9 billion acquisition of Alpine Immune Sciences highlights its aggressive investment in the immuno-oncology sector, signaling strong confidence in the market's growth potential and the value of innovative assets. MRK Merck's significant R&D investment (USD 11.15 billion) and 25 registrational studies in early-stage settings demonstrate a strong commitment to immuno-oncology as a primary growth engine, with Keytruda showing broad market dominance. BMY GILD Gilead is scaling its CAR-T treatment capacity to 24,000 annual treatments, indicating significant expansion and investment in the immuno-oncology space, driven by market demand and therapeutic advancements. JNJ AZN AstraZeneca's USD 2.4 billion acquisition of Fusion Pharmaceuticals signifies a strategic expansion into radiopharmaceuticals within the immuno-oncology market, indicating a bullish outlook on acquiring innovative capabilities. NVS Novartis's strategic deals, including a USD 3.0 billion licensing deal with Dren Bio and a USD 2.9 billion acquisition of MorphoSys, highlight its aggressive expansion and investment in immuno-oncology pipeline assets. REGN While Regeneron is a major player in biopharmaceuticals, the article does not provide specific details on its current activities or sentiment within the immuno-oncology market, beyond general industry trends. AMGN The article mentions CAR-T therapies and general market growth, but does not provide specific details or sentiment regarding Amgen's current involvement or performance in the immuno-oncology sector. PFE Pfizer is a major pharmaceutical company, but the article does not mention specific drugs, investments, or sentiment related to its activities in the immuno-oncology market. BIIB The article focuses on immuno-oncology and does not provide specific information or sentiment regarding Biogen's current position or activities in this market. ISRG While Intuitive Surgical is involved in surgical technology, the article's focus on immuno-oncology drugs and treatments does not provide specific sentiment or details about the company's performance in this area. MDLZ Mondelez International operates in the consumer goods sector and is not mentioned in the article, which focuses exclusively on the immuno-oncology drugs market. IMCR Immunocore reported positive results with partial tumor responses in a dual-targeting antibody trial presented at ASCO 2024, indicating promising developments in the immuno-oncology space. CRSP While CRISPR technology has potential applications in oncology, the article does not specifically mention CRISPR Therapeutics or its immuno-oncology efforts. EDIT Similar to CRISPR Therapeutics, Editas Medicine's gene editing technology could be relevant, but the article does not provide specific details or sentiment regarding its immuno-oncology activities. NCLH Norwegian Cruise Line Holdings operates in the travel industry and is not relevant to the immuno-oncology drugs market discussed in the article. ACRS Aclaris Therapeutics focuses on inflammatory and autoimmune diseases, not specifically immuno-oncology as detailed in the article. ALNY Alnylam Pharmaceuticals specializes in RNA interference (RNAi) therapeutics, and the article does not provide specific information on its immuno-oncology activities. INCY Incyte is a key player in the immuno-oncology space, particularly with its JAK inhibitors and involvement in CAR-T therapies. The article's positive outlook on the sector suggests a bullish sentiment for companies like Incyte. ABBV LULU Lululemon is a retail company focused on athletic apparel and is not mentioned in the article concerning the immuno-oncology market. EXAS Exact Sciences focuses on cancer diagnostics, particularly early detection. While relevant to oncology, the article's focus is on drug development and market growth, not diagnostics specifically. RDVY ONCY OncoCyte Corporation is involved in cancer diagnostics, but the article's focus is on immuno-oncology drugs and market growth, not diagnostics specifically. GENM DTIL The article does not mention Detai or provide any information relevant to its performance or sentiment in the immuno-oncology market. XAIR Xaira Therapeutics raised USD 1.0 billion in Series A financing, one of the largest of 2024, indicating strong investor confidence and significant capital deployment in the immuno-oncology space. CGEN The article does not mention CGEN or provide any information relevant to its performance or sentiment in the immuno-oncology market. ADPT The article does not mention Adapte or provide any information relevant to its performance or sentiment in the immuno-oncology market. ATRC AtriCure develops surgical ablation systems for cardiac arrhythmias and is not relevant to the immuno-oncology drugs market. CODX Co-Diagnostics focuses on molecular diagnostic tests and is not directly involved in immuno-oncology drug development as described in the article. CORT Corcept Therapeutics focuses on developing treatments for metabolic, endocrine, and oncologic indications, but the article does not provide specific sentiment for its immuno-oncology efforts. CRBU Caribou Biosciences is developing CAR-T cell therapies, a significant area within immuno-oncology discussed in the article. The overall market growth suggests a positive outlook for such companies. CTAS Cintas Corporation provides business services and is not relevant to the immuno-oncology drugs market. CYTK Cytokinetics focuses on muscle and heart diseases, not immuno-oncology drugs as described in the article. DASH DoorDash operates in the food delivery sector and is not relevant to the immuno-oncology drugs market. DECK Deckers Outdoor Corporation designs and markets footwear and apparel, and is not relevant to the immuno-oncology drugs market. DOCU DocuSign provides e-signature solutions and is not relevant to the immuno-oncology drugs market. EBAY eBay is an e-commerce platform and is not relevant to the immuno-oncology drugs market. ELAN Elanco Animal Health focuses on animal health products and is not relevant to the immuno-oncology drugs market. ENPH Enphase Energy is a solar technology company and is not relevant to the immuno-oncology drugs market. EPAM EPAM Systems provides software engineering and digital platform services, and is not directly involved in immuno-oncology drug development. FIVN Five9 provides cloud contact center software and is not relevant to the immuno-oncology drugs market. FORM FormFactor provides semiconductor test and measurement solutions, and is not relevant to the immuno-oncology drugs market. FTNT Fortinet provides cybersecurity solutions and is not relevant to the immuno-oncology drugs market. GDRX GoodRx Holdings provides prescription drug pricing information and coupons, and is not directly involved in immuno-oncology drug development. GEHC GE HealthCare Technologies provides medical imaging, diagnostics, and monitoring solutions. While relevant to healthcare, the article does not provide specific sentiment for its immuno-oncology drug activities. GNTX Gentex Corporation manufactures automotive, aerospace, and fire protection products, and is not relevant to the immuno-oncology drugs market. GOOS Canada Goose Holdings designs and manufactures outerwear and is not relevant to the immuno-oncology drugs market. GRMN Garmin develops GPS technology and consumer electronics, and is not relevant to the immuno-oncology drugs market. GTLB GitLab provides a DevOps platform and is not relevant to the immuno-oncology drugs market. HGV Hilton Grand Vacations operates in the timeshare industry and is not relevant to the immuno-oncology drugs market. HLT Hilton Worldwide Holdings operates in the hospitality industry and is not relevant to the immuno-oncology drugs market. HOLX Hologic focuses on women's health diagnostics and medical devices, and the article does not provide specific sentiment for its immuno-oncology activities. HON Honeywell International is a diversified technology and manufacturing company, not directly involved in immuno-oncology drug development. HPE Hewlett Packard Enterprise provides IT infrastructure and services, and is not relevant to the immuno-oncology drugs market. HPQ HP Inc. designs and manufactures personal computers and printers, and is not relevant to the immuno-oncology drugs market. HRB H&R Block provides tax preparation services and is not relevant to the immuno-oncology drugs market. HSIC Henry Schein is a distributor of healthcare products and services, and the article does not provide specific sentiment for its immuno-oncology drug activities. HWM Howmet Aerospace manufactures engineered metal products and is not relevant to the immuno-oncology drugs market. IDXX IDEXX Laboratories provides diagnostic and software products for veterinary professionals, and is not relevant to the immuno-oncology drugs market. ILMN Illumina is a leader in DNA sequencing and array-based technologies. While relevant to research, the article does not provide specific sentiment for its immuno-oncology drug activities. INSM Insmed focuses on rare diseases and specialty conditions, and the article does not provide specific sentiment for its immuno-oncology efforts. INTC Intel is a semiconductor manufacturer and is not relevant to the immuno-oncology drugs market. INTU Intuit provides financial software and is not relevant to the immuno-oncology drugs market. IRTC The article does not mention Integrity Applications or provide any information relevant to its performance or sentiment in the immuno-oncology market. ITRI Itron provides technology solutions for utilities and is not relevant to the immuno-oncology drugs market. IVZ Invesco is an investment management company and is not directly involved in immuno-oncology drug development. JBL Jabil Inc. provides manufacturing solutions and services, and is not relevant to the immuno-oncology drugs market. JEF JHG Janus Henderson Group is an investment management company and is not directly involved in immuno-oncology drug development. JLL Jones Lang LaSalle provides commercial real estate services and is not relevant to the immuno-oncology drugs market. JPM JPMorgan Chase & Co. is a financial services firm. While involved in financing, the article does not provide specific sentiment for its role in the immuno-oncology market. KDP Keurig Dr Pepper is a beverage company and is not relevant to the immuno-oncology drugs market. KHC Kraft Heinz is a food and beverage company and is not relevant to the immuno-oncology drugs market. KODK Eastman Kodak is involved in imaging and printing technology, and is not relevant to the immuno-oncology drugs market. LAKE The article does not mention LAKE or provide any information relevant to its performance or sentiment in the immuno-oncology market. LCID Lucid Group manufactures electric vehicles and is not relevant to the immuno-oncology drugs market. LRCX Lam Research provides wafer fabrication equipment and services for the semiconductor industry, and is not relevant to the immuno-oncology drugs market. LSCC Lattice Semiconductor designs and manufactures FPGAs and is not relevant to the immuno-oncology drugs market. LYFT Lyft operates a ride-sharing platform and is not relevant to the immuno-oncology drugs market. MCHP Microchip Technology designs and manufactures microcontrollers, FPGAs, and analog semiconductors, and is not relevant to the immuno-oncology drugs market. MELI MercadoLibre is an e-commerce and fintech company operating in Latin America, and is not relevant to the immuno-oncology drugs market. MGM MGM Resorts International operates casino resorts and is not relevant to the immuno-oncology drugs market. MKTX MarketAxess Holdings operates an electronic trading platform for fixed income securities and is not relevant to the immuno-oncology drugs market. MLCO Molecular Partners develops protein-based therapeutics. While relevant to drug development, the article does not provide specific sentiment for its immuno-oncology activities. MNST Monster Beverage produces energy drinks and is not relevant to the immuno-oncology drugs market. MRVL Marvell Technology designs and manufactures semiconductor solutions, and is not relevant to the immuno-oncology drugs market. MTCH Match Group operates dating apps and websites, and is not relevant to the immuno-oncology drugs market. MU Micron Technology manufactures memory and storage products, and is not relevant to the immuno-oncology drugs market. NDSN Nordson Corporation designs and manufactures dispensing, sealing, and other equipment, and is not relevant to the immuno-oncology drugs market. NEO NeoGames S.A. provides lottery and gaming solutions, and is not relevant to the immuno-oncology drugs market. NET Cloudflare provides content delivery network and security services, and is not relevant to the immuno-oncology drugs market. NFLX Netflix is a streaming entertainment service and is not relevant to the immuno-oncology drugs market. NKE Nike designs and sells athletic footwear and apparel, and is not relevant to the immuno-oncology drugs market. NOC Northrop Grumman is an aerospace and defense company, and is not relevant to the immuno-oncology drugs market. NOW ServiceNow provides cloud computing services for IT service management and is not relevant to the immuno-oncology drugs market. NRG NRG Energy is a diversified power company and is not relevant to the immuno-oncology drugs market. NTAP NetApp provides cloud data services and storage solutions, and is not relevant to the immuno-oncology drugs market. NTES NetEase is a Chinese internet technology company and is not relevant to the US immuno-oncology market. NVDA NVIDIA is a leader in AI and graphics processing, which can support drug discovery, but the article does not provide specific sentiment for its role in immuno-oncology. NXPI NXP Semiconductors designs and manufactures automotive, industrial, and communication solutions, and is not relevant to the immuno-oncology drugs market. ODFL Old Dominion Freight Line is a transportation company and is not relevant to the immuno-oncology drugs market. OMC Omnicom Group is a global advertising, marketing, and corporate communications company, and is not relevant to the immuno-oncology drugs market. ON ON Semiconductor provides intelligent sensing and power solutions, and is not relevant to the immuno-oncology drugs market. ORCL Oracle provides cloud technology and enterprise software, and is not directly involved in immuno-oncology drug development. ORLY O'Reilly Automotive is a retailer of automotive aftermarket parts and is not relevant to the immuno-oncology drugs market. OSK Oshkosh Corporation designs and manufactures specialty vehicles and equipment, and is not relevant to the immuno-oncology drugs market. OTIS Otis Worldwide manufactures and services elevators and escalators, and is not relevant to the immuno-oncology drugs market. OXY Occidental Petroleum is an oil and gas exploration and production company, and is not relevant to the immuno-oncology drugs market. PANW Palo Alto Networks provides cybersecurity solutions, and is not relevant to the immuno-oncology drugs market. PAYX Paychex provides human resource, payroll, and benefits outsourcing services, and is not relevant to the immuno-oncology drugs market. PCAR PACCAR manufactures and markets light-, medium-, and heavy-duty trucks, and is not relevant to the immuno-oncology drugs market. PCG PG&E Corporation is an energy company and is not relevant to the immuno-oncology drugs market. PDD Pinduoduo is a Chinese e-commerce company and is not relevant to the US immuno-oncology market. PEP PepsiCo is a global food and beverage company and is not relevant to the immuno-oncology drugs market. PGR ProAssurance Corporation provides professional liability insurance, and is not relevant to the immuno-oncology drugs market. PH The article does not mention Pinnacle or provide any information relevant to its performance or sentiment in the immuno-oncology market. PHG Philips is a health technology company, but the article does not provide specific sentiment for its immuno-oncology drug activities. PII Polaris Inc. manufactures off-road vehicles, snowmobiles, and motorcycles, and is not relevant to the immuno-oncology drugs market. PKX Puxin Limited is a Chinese education company and is not relevant to the US immuno-oncology market. PLAB Photronics manufactures photomasks for the semiconductor industry, and is not relevant to the immuno-oncology drugs market. PLD Prologis is a real estate company focused on logistics facilities, and is not relevant to the immuno-oncology drugs market. PLUG Plug Power is involved in hydrogen fuel cell systems and is not relevant to the immuno-oncology drugs market. PM Philip Morris International is a tobacco company and is not relevant to the immuno-oncology drugs market. PNW Pinnacle West Capital is an electric utility company and is not relevant to the immuno-oncology drugs market. POOL Pool Corporation is a distributor of swimming pool supplies and is not relevant to the immuno-oncology drugs market. POST Post Holdings is a consumer packaged goods company and is not relevant to the immuno-oncology drugs market. PPG PPG Industries is a global supplier of paints, coatings, and specialty materials, and is not relevant to the immuno-oncology drugs market. PPL PPL Corporation is an energy company and is not relevant to the immuno-oncology drugs market. PRGS Progress Software provides application development and deployment software, and is not relevant to the immuno-oncology drugs market. PRGO Perrigo Company develops and manufactures consumer self-care products and is not directly involved in immuno-oncology drug development. PRLB Proto Labs provides on-demand manufacturing services and is not relevant to the immuno-oncology drugs market. PRO PRTA Portola Pharmaceuticals was acquired by Alexion Pharmaceuticals in 2020. The article does not provide specific sentiment for its immuno-oncology activities. PSFE Paysafe Limited provides digital payment solutions and is not relevant to the immuno-oncology drugs market. PSNY Polestar Automotive designs and manufactures electric vehicles and is not relevant to the immuno-oncology drugs market. PTC PTC Inc. provides software for product lifecycle management and is not relevant to the immuno-oncology drugs market. PVH PVH Corp. designs and markets apparel and accessories, and is not relevant to the immuno-oncology drugs market. QCOM Qualcomm designs and manufactures semiconductors and telecommunications equipment, and is not relevant to the immuno-oncology drugs market. QGEN Qiagen provides sample and assay technologies for molecular diagnostics, and the article does not provide specific sentiment for its immuno-oncology drug activities. QRVO Qorvo designs and manufactures radio-frequency systems and components, and is not relevant to the immuno-oncology drugs market. RBLX Roblox is an online game platform and is not relevant to the immuno-oncology drugs market. RCL Royal Caribbean Cruises operates cruise ships and is not relevant to the immuno-oncology drugs market. RDNT RadNet provides outpatient diagnostic imaging services. While related to healthcare, the article does not provide specific sentiment for its immuno-oncology drug activities. REI The article does not mention Retail or provide any information relevant to its performance or sentiment in the immuno-oncology market. REIT RF Regions Financial is a bank holding company and is not relevant to the immuno-oncology drugs market. RGEN Repligen Corporation provides bioprocessing technologies. While it serves the biopharma industry, the article does not provide specific sentiment for its immuno-oncology drug activities. RIVN Rivian Automotive designs and manufactures electric vehicles and is not relevant to the immuno-oncology drugs market. RL Ralph Lauren Corporation designs and markets lifestyle products and is not relevant to the immuno-oncology drugs market. RMBS Rambus designs and develops high-speed memory interface chips and is not relevant to the immuno-oncology drugs market. RMD ResMed develops cloud-connectable devices for treating sleep apnea and other respiratory conditions, and is not relevant to the immuno-oncology drugs market. ROBT ROKU Roku operates a digital media platform and is not relevant to the immuno-oncology drugs market. ROST Ross Stores is a retailer of apparel and home fashions and is not relevant to the immuno-oncology drugs market. RPRX Royalty Pharma provides capital to life sciences companies. While it invests in the sector, the article does not provide specific sentiment for its immuno-oncology activities. RS Reliance Steel & Aluminum is a metals service center and is not relevant to the immuno-oncology drugs market. RSG Republic Services provides waste management services and is not relevant to the immuno-oncology drugs market. RSP RVSN Revance Therapeutics develops aesthetic and therapeutic treatments, and the article does not provide specific sentiment for its immuno-oncology efforts. RYAAY Ryanair Holdings is an Irish airline and is not relevant to the US immuno-oncology market. S Sprouts Farmers Market is a grocery store chain and is not relevant to the immuno-oncology drugs market. SABR Sabre Corporation provides technology solutions for the travel industry and is not relevant to the immuno-oncology drugs market. SAN Banco Santander is a Spanish banking group and is not relevant to the US immuno-oncology market. SAVA Cassava Sciences is developing treatments for neurodegenerative diseases, and the article does not provide specific sentiment for its immuno-oncology efforts. SBAC SBA Communications owns and operates wireless communications infrastructure and is not relevant to the immuno-oncology drugs market. SBRA Sabra Health Care REIT invests in healthcare real estate and is not directly involved in immuno-oncology drug development. SBUX Starbucks is a coffeehouse chain and is not relevant to the immuno-oncology drugs market. SCHD SCL Sensient Technologies produces colors, flavors, and fragrances, and is not relevant to the immuno-oncology drugs market. SD Suncor Energy is a Canadian energy company and is not relevant to the US immuno-oncology market. SE Sea Limited is a Singaporean internet company and is not relevant to the US immuno-oncology market. SEDG SolarEdge Technologies designs and manufactures solar inverters and is not relevant to the immuno-oncology drugs market. SEE Sealed Air Corporation provides packaging solutions and is not relevant to the immuno-oncology drugs market. SEIC SEI Investments provides investment processing, administration, and technology solutions, and is not directly involved in immuno-oncology drug development. SELF Global Self Storage operates self-storage facilities and is not relevant to the immuno-oncology drugs market. SEM Semtech Corporation designs and manufactures analog and mixed-signal semiconductors, and is not relevant to the immuno-oncology drugs market. SIRI Sirius XM Holdings provides satellite radio services and is not relevant to the immuno-oncology drugs market. SJM J.M. Smucker is a manufacturer of consumer food products and is not relevant to the immuno-oncology drugs market. SKX SLB Schlumberger provides technology for the oil and gas industry and is not relevant to the immuno-oncology drugs market. SLGN Silgan Holdings manufactures rigid metal and plastic containers and is not relevant to the immuno-oncology drugs market. SMCI Super Micro Computer designs and manufactures high-performance server and storage solutions, and is not directly involved in immuno-oncology drug development. SMLR Semler Scientific provides hardware, software, and services for the healthcare industry, but the article does not provide specific sentiment for its immuno-oncology activities. SNBR Sleep Number Corporation designs and sells mattresses and bedding products, and is not relevant to the immuno-oncology drugs market. SNOW Snowflake provides cloud-based data warehousing solutions, and is not directly involved in immuno-oncology drug development. SNPS Synopsys provides electronic design automation tools and is not relevant to the immuno-oncology drugs market. SO Southern Company is an electric utility company and is not relevant to the immuno-oncology drugs market. SONO Sonos designs and manufactures audio products and is not relevant to the immuno-oncology drugs market. SPCE Virgin Galactic Holdings is involved in spaceflight and is not relevant to the immuno-oncology drugs market. SPGI S&P Global provides financial information and analytics, and the article does not provide specific sentiment for its role in the immuno-oncology market. SPNS The article does not mention Suprema or provide any information relevant to its performance or sentiment in the immuno-oncology market. SQM Sociedad Quimica y Minera is a Chilean chemical company and is not relevant to the US immuno-oncology market. SRPT Sarepta Therapeutics focuses on gene therapies for rare diseases, and the article does not provide specific sentiment for its immuno-oncology efforts. SSNC SS&C Technologies provides software and services for the financial services industry, and is not directly involved in immuno-oncology drug development. ST The article does not mention Star or provide any information relevant to its performance or sentiment in the immuno-oncology market. STAG STAG Industrial is a real estate investment trust focused on industrial properties and is not relevant to the immuno-oncology drugs market. STLD Steel Dynamics is a steel producer and is not relevant to the immuno-oncology drugs market. STNG Stingray Group is a Canadian music and entertainment company and is not relevant to the US immuno-oncology market. STOK Stoke Therapeutics focuses on treating rare genetic diseases, and the article does not provide specific sentiment for its immuno-oncology efforts. STX Seagate Technology designs and manufactures data storage solutions, and is not relevant to the immuno-oncology drugs market. SUN Sunoco LP is a master limited partnership that distributes motor fuels and is not relevant to the immuno-oncology drugs market. SWKS Skyworks Solutions designs and manufactures analog semiconductors, and is not relevant to the immuno-oncology drugs market. SYK Stryker Corporation develops medical technologies and products, and the article does not provide specific sentiment for its immuno-oncology drug activities. SYY The Simply Good Foods Company produces convenient, better-for-you snacks and is not relevant to the immuno-oncology drugs market. T AT&T Inc. provides telecommunications services and is not relevant to the immuno-oncology drugs market. TAL TAL Education Group is a Chinese educational services provider and is not relevant to the US immuno-oncology market. TAN TCOM Trip.com Group is a Chinese online travel agency and is not relevant to the US immuno-oncology market. TDOC Teladoc Health provides telehealth services and is not directly involved in immuno-oncology drug development. TECK Teck Resources is a Canadian diversified resource company and is not relevant to the US immuno-oncology market. TEF Telefonica is a Spanish telecommunications company and is not relevant to the US immuno-oncology market. TEK TEL TE Connectivity designs and manufactures connectors and sensors, and is not relevant to the immuno-oncology drugs market. TER Teradyne designs and manufactures automatic test equipment, and is not relevant to the immuno-oncology drugs market. TFX Tactile Systems Technology develops medical devices for treating sleep apnea and other conditions, and is not relevant to the immuno-oncology drugs market. TGT Target Corporation is a retail company and is not relevant to the immuno-oncology drugs market. TGTX TG Therapeutics is developing novel therapies for B-cell malignancies, including immuno-oncology approaches. The strong market growth suggests a positive outlook. THC Healthcare Trust of America is a real estate investment trust focused on medical office buildings and is not directly involved in immuno-oncology drug development. THO Thor Industries manufactures recreational vehicles and is not relevant to the immuno-oncology drugs market. TIGR The article does not mention Tiger or provide any information relevant to its performance or sentiment in the immuno-oncology market. TITN Titan International manufactures wheels, tires, and undercarriage for off-highway vehicles and is not relevant to the immuno-oncology drugs market. TJX The TJX Companies operates off-price retail stores and is not relevant to the immuno-oncology drugs market. TLRY Tilray Brands is a Canadian pharmaceutical and cannabis company and is not relevant to the US immuno-oncology market. TMO Thermo Fisher Scientific provides scientific instrumentation, reagents, and consumables. While it supports research, the article does not provide specific sentiment for its immuno-oncology drug activities. TMUS T-Mobile US is a wireless network operator and is not relevant to the immuno-oncology drugs market. TNDM Tandem Diabetes Care develops insulin pump systems for diabetes management and is not relevant to the immuno-oncology drugs market. TNET Trinet Group provides human resources solutions for small and medium-sized businesses and is not relevant to the immuno-oncology drugs market. TOL Toll Brothers is a luxury home builder and is not relevant to the immuno-oncology drugs market. TOPS Top Ships owns and operates oil and chemical tankers, and is not relevant to the immuno-oncology drugs market. TORO The Toro Company designs, manufactures, and markets turf and environmental equipment, and is not relevant to the immuno-oncology drugs market. TPH TriPointe Homes is a homebuilder and is not relevant to the immuno-oncology drugs market. TPL Tri-Pointe Group is a homebuilder and is not relevant to the immuno-oncology drugs market. TQQQ TR Trimas Corporation manufactures industrial and consumer products, and is not relevant to the immuno-oncology drugs market. TRC Terex Corporation manufactures equipment for the construction and mining industries, and is not relevant to the immuno-oncology drugs market. TRIP TripAdvisor is an online travel company and is not relevant to the immuno-oncology drugs market. TRMB Trimble provides positioning, modeling, and connectivity solutions, and is not relevant to the immuno-oncology drugs market. TRMK Trustmark Corporation is a financial services company and is not relevant to the immuno-oncology drugs market. TRN Trinity Industries manufactures railcars and provides railcar leasing and services, and is not relevant to the immuno-oncology drugs market. TRP TransAlta is a Canadian electricity generation company and is not relevant to the US immuno-oncology market. TRT Transcat provides calibration and compliance services for regulated industries, and is not directly involved in immuno-oncology drug development. TRVG The article does not mention Trade Group or provide any information relevant to its performance or sentiment in the immuno-oncology market. TS Tenaris is a producer of steel pipes for the energy industry and is not relevant to the immuno-oncology drugs market. TSCO Tractor Supply Company is a retailer of agricultural and home supplies and is not relevant to the immuno-oncology drugs market. TSE The Shyft Group manufactures specialty vehicles and is not relevant to the immuno-oncology drugs market. TSLA Tesla is an electric vehicle and clean energy company and is not relevant to the immuno-oncology drugs market. TSN Tyson Foods is a producer of protein and is not relevant to the immuno-oncology drugs market. TT Trane Technologies manufactures heating, ventilation, and air conditioning systems, and is not relevant to the immuno-oncology drugs market. TTC Tutor Perini is a construction company and is not relevant to the immuno-oncology drugs market. TTD The Trade Desk operates a technology platform for advertising and is not relevant to the immuno-oncology drugs market. TTI Tetra Technologies provides water and flow management solutions, and is not relevant to the immuno-oncology drugs market. TTNP TTWO Take-Two Interactive Software is a video game company and is not relevant to the immuno-oncology drugs market. TU Tupperware Brands manufactures and sells food storage containers and is not relevant to the immuno-oncology drugs market. TUSK Mammoth Energy Services provides services to the oil and gas industry and is not relevant to the immuno-oncology drugs market. TV TransUnion is a consumer credit reporting agency and is not relevant to the immuno-oncology drugs market. TVC TVE TW Ternium is a Latin American steel company and is not relevant to the US immuno-oncology market. TWLO Twilio provides a cloud communications platform and is not relevant to the immuno-oncology drugs market. TX Teradyne designs and manufactures automatic test equipment, and is not relevant to the immuno-oncology drugs market. TXN Texas Instruments designs and manufactures semiconductors, and is not relevant to the immuno-oncology drugs market. TXRH Texas Roadhouse is a restaurant chain and is not relevant to the immuno-oncology drugs market. TXT Textron is a multi-industry company with businesses in aerospace, defense, and industrial products, and is not relevant to the immuno-oncology drugs market. TYL Tyler Technologies provides software and services to the public sector and is not relevant to the immuno-oncology drugs market. U Unity Software develops a real-time development platform and is not relevant to the immuno-oncology drugs market. UAL United Airlines Holdings is an airline company and is not relevant to the immuno-oncology drugs market. UBER Uber Technologies operates a ride-sharing and delivery platform and is not relevant to the immuno-oncology drugs market. UDR UDR, Inc. is a real estate investment trust that owns and manages apartment communities, and is not relevant to the immuno-oncology drugs market. UEC Uranium Energy Corp. is involved in uranium mining and is not relevant to the immuno-oncology drugs market. UHAL U-Haul Holding Company provides moving equipment and storage services, and is not relevant to the immuno-oncology drugs market. ULTA Ulta Beauty is a retailer of cosmetics and beauty products, and is not relevant to the immuno-oncology drugs market. UMC United Microelectronics Corporation is a Taiwanese semiconductor foundry and is not relevant to the US immuno-oncology market. UMH UMH Properties is a real estate investment trust that owns and operates manufactured home communities, and is not relevant to the immuno-oncology drugs market. UNFI United Natural Foods is a distributor of natural and organic foods and is not relevant to the immuno-oncology drugs market. UNH UnitedHealth Group is a diversified healthcare company, but the article does not provide specific sentiment for its immuno-oncology drug activities. UNIT Unit Corporation is an energy company and is not relevant to the immuno-oncology drugs market. UNM Unum Group provides financial protection benefits and is not relevant to the immuno-oncology drugs market. UPST Upstart Holdings operates an AI-powered lending platform and is not relevant to the immuno-oncology drugs market. URBN Urban Outfitters is a lifestyle retail company and is not relevant to the immuno-oncology drugs market. USA USFD US Foods Holding is a food service distributor and is not relevant to the immuno-oncology drugs market. USNA USANA Health Sciences develops and manufactures nutritional supplements and is not directly involved in immuno-oncology drug development. USPH U.S. Physical Therapy operates outpatient physical and occupational therapy clinics and is not relevant to the immuno-oncology drugs market. UTHR United Therapeutics develops therapies for life-threatening conditions, and the article does not provide specific sentiment for its immuno-oncology efforts. V Visa is a global payments technology company and is not relevant to the immuno-oncology drugs market. VRSK Verisk Analytics provides data analytics and risk assessment services, and is not directly involved in immuno-oncology drug development. VTR Viatris (formed from Mylan and Upjohn) is a global healthcare company, but the article does not provide specific sentiment for its immuno-oncology activities. VTRS Viatris (formed from Mylan and Upjohn) is a global healthcare company, but the article does not provide specific sentiment for its immuno-oncology activities. VZ Verizon Communications is a telecommunications company and is not relevant to the immuno-oncology drugs market. W Wayfair is an e-commerce company specializing in home goods and is not relevant to the immuno-oncology drugs market. WAB Wabtec Corporation provides technology solutions for the rail industry and is not relevant to the immuno-oncology drugs market. WDC Western Digital designs and manufactures data storage devices and is not relevant to the immuno-oncology drugs market. WEC WEC Energy Group is an energy company and is not relevant to the immuno-oncology drugs market. WELL Welltower Inc. is a real estate investment trust focused on healthcare properties and is not directly involved in immuno-oncology drug development. WEN Wendy's Company is a fast-food restaurant chain and is not relevant to the immuno-oncology drugs market. WERN Werner Enterprises is a transportation and logistics company and is not relevant to the immuno-oncology drugs market. WEX WEX Inc. provides corporate payment solutions and is not relevant to the immuno-oncology drugs market. WFC Wells Fargo is a financial services company. While involved in financing, the article does not provide specific sentiment for its role in the immuno-oncology market. WGO Winnebago Industries manufactures recreational vehicles and is not relevant to the immuno-oncology drugs market. WHD The article does not mention WHD or provide any information relevant to its performance or sentiment in the immuno-oncology market. WHR Whirlpool Corporation is a manufacturer and marketer of home appliances and is not relevant to the immuno-oncology drugs market. WIA WMB The Williams Companies is an energy infrastructure company and is not relevant to the immuno-oncology drugs market. WMT Walmart is a retail corporation and is not relevant to the immuno-oncology drugs market. WNS WPC W.P. Carey is a real estate investment trust and is not directly involved in immuno-oncology drug development. WRB WST West Pharmaceutical Services designs and manufactures advanced packaging solutions for the pharmaceutical industry. While relevant, the article does not provide specific sentiment for its immuno-oncology drug activities. WTAI WTFC Washington Trust Bancorp is a bank holding company and is not relevant to the immuno-oncology drugs market. WTS The article does not mention WTS or provide any information relevant to its performance or sentiment in the immuno-oncology market. WU Western Union is a financial services company and is not relevant to the immuno-oncology drugs market. WY Weyerhaeuser is a real estate investment trust that owns and manages timberlands, and is not relevant to the immuno-oncology drugs market. WYNN Wynn Resorts operates casino resorts and is not relevant to the immuno-oncology drugs market. XBIT Xometry Inc. operates a marketplace for custom manufacturing and is not relevant to the immuno-oncology drugs market. XCUR The article does not mention Excur or provide any information relevant to its performance or sentiment in the immuno-oncology market. XENE Xenon Pharmaceuticals focuses on developing treatments for neurological disorders, and the article does not provide specific sentiment for its immuno-oncology efforts. XFLT XGN Exagen Inc. provides diagnostic testing for autoimmune diseases, and the article does not provide specific sentiment for its immuno-oncology activities. XHR Xenia Hotels & Resorts is a real estate investment trust that owns luxury hotels and is not relevant to the immuno-oncology drugs market. XLP XOM Exxon Mobil is an oil and gas company and is not relevant to the immuno-oncology drugs market. XPO XPO Logistics provides freight transportation and logistics services, and is not relevant to the immuno-oncology drugs market. XRAY DENTSPLY SIRONA develops and manufactures dental products and equipment, and is not relevant to the immuno-oncology drugs market. XRT XTLB The article does not mention XTL Biologics or provide any information relevant to its performance or sentiment in the immuno-oncology market. XXII 22nd Century Group develops reduced-nicotine tobacco and hemp/cannabis plants, and is not relevant to the immuno-oncology drugs market. XYL Xylem Inc. provides water technology solutions and is not relevant to the immuno-oncology drugs market. YETI YETI Holdings manufactures and distributes coolers, drinkware, and outdoor equipment, and is not relevant to the immuno-oncology drugs market. YMM Y-mAbs Therapeutics develops antibody-based therapies for cancer. The strong growth in the immuno-oncology market suggests a positive outlook for companies like Y-mAbs. YPF YPF Sociedad Anonima is an Argentine energy company and is not relevant to the US immuno-oncology market. YUM Yum! Brands operates fast-food chains and is not relevant to the immuno-oncology drugs market. Z Zillow Group is an online real estate marketplace and is not relevant to the immuno-oncology drugs market. ZBRA Zebra Technologies designs and manufactures marking, tracking, and computer printing technologies, and is not relevant to the immuno-oncology drugs market. ZCMD Zhongchao is a Chinese company focused on healthcare services and is not relevant to the US immuno-oncology market. ZIM ZIM Integrated Shipping Services is an Israeli international cargo shipping company and is not relevant to the US immuno-oncology market. ZION Zions Bancorporation is a bank holding company and is not relevant to the immuno-oncology drugs market. ZKIN ZK International Group is a Chinese company involved in industrial activities and is not relevant to the US immuno-oncology market. ZNTL Zentalis Pharmaceuticals is developing novel cancer therapies, including immuno-oncology approaches. The overall market growth suggests a positive outlook for such companies. ZTO ZTO Express is a Chinese express delivery company and is not relevant to the US immuno-oncology market. ZTS ZYME Zymeworks is developing antibody-drug conjugates and bispecific antibodies, key areas in immuno-oncology. The article's positive outlook on the market suggests potential for growth.

Chicago, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The global immuno-oncology drugs market was valued at US$ 35.78 billion in 2025 and is expected to reach US$ 185.69 billion by 2035, growing at a CAGR of 17.9% during the forecast period 2026–2035.

Curative intent is aggressively reshaping the investment and operational landscape of the immuno-oncology drugs market. Clinical volume drives this shift, evidenced by 6,528 oncology trials projected to complete in 2024. Regulatory bodies such as FDA are amplifying this demand, issuing 60+ oncology approvals in 2024, including 11 first-in-class therapeutics. The transition from palliative care is fueling massive capital injections, such as Vertex’s USD 4.9 billion acquisition of Alpine and the USD 10.3 billion raised across 169 venture rounds in 2024.

Request Sample Pages: https://www.astuteanalytica.com/request-sample/immuno-oncology-drugs-market

Commercial success in targeted therapies is validating these high stakes in the immuno-oncology drugs market. Enhertu alone generated USD 3.75 billion in 2024 sales, proving the profitability of "smart chemotherapy." The industry is responding with deep pipelines, including 600+ bispecific antibodies in development and 25 registrational studies by Merck in early-stage settings. Bristol Myers Squibb’s USD 11.15 billion R&D spend further confirms that major players view this sector as their primary growth engine.

to accommodate this demand, Infrastructure around the world is expanding rapidly. For instance, Gilead is scaling to 24,000 annual CAR-T treatments, while Nucleus RadioPharma added 100,000 square feet of capacity. Administrative frameworks are also adapting, with 230 new CPT codes added in 2024 to facilitate reimbursement. With 44,000+ stakeholders attending ASCO 2024, the ecosystem is fully mobilized to support next-generation immuno-oncology delivery.

Key Findings

Immune Checkpoint Inhibitors Secure Market Supremacy via Broad Label Expansion

By treatment type, the Immune Checkpoint Inhibitors (ICIs) segment maintained an unassailable lead in immuno-oncology drugs market. This dominance is not static, it is actively evolving through aggressive label expansions into earlier lines of therapy. While CAR-T cell therapies grabbed headlines, PD-1 and PD-L1 inhibitors like Keytruda (pembrolizumab) and Opdivo (nivolumab) remained the financial bedrock of the industry, generating combined sales exceeding $40 billion.

The segment’s stronghold in 2024 was fortified by a paradigm shift: the move from treating metastatic disease to "adjuvant" and "perioperative" settings (treating before and after surgery). This strategy effectively tripled the duration of therapy for eligible patients, directly correlating to higher revenue per script. Furthermore, 2024 marked the rise of "next-gen" checkpoints, specifically bispecific antibodies. The disruptive success of Ivonescimab (PD-1/VEGF), which demonstrated superior efficacy over standard-of-care monotherapies in head-to-head trials during late 2024, signaled that the ICI segment is regenerating its own growth pipeline rather than ceding ground to other modalities.

By Disease Type, Lung Cancer Segment Leads Revenue with Perioperative Immunotherapy Adoption

By disease type, the Lung Cancer segment remained the undisputed market leader in immuno-oncology drugs market. This leadership is driven by the sheer scale of the patient population—lung cancer remains the leading cause of cancer-related mortality worldwide—combined with the near-universal adoption of immunotherapy for Non-Small Cell Lung Cancer (NSCLC). The 2024 revenue surge was specifically catalyzed by the widespread implementation of perioperative immunotherapy regimens. Following pivotal FDA approvals, oncologists began routinely administering chemo-immunotherapy combinations to patients with resectable stages II and III lung cancer, a patient pool that was previously treated with surgery alone. This clinical shift has entrenched immunotherapies as a non-negotiable standard of care across the entire disease continuum, not just late-stage palliative care.

Additionally, the Small Cell Lung Cancer (SCLC) sub-segment contributed new growth due to the uptake of tarlatamab, a DLL3-targeting bispecific T-cell engager approved in mid-2024, which offered the first major survival breakthrough for this aggressive subtype in decades, further expanding the segment’s financial footprint.

By Distribution, Hospital Pharmacies Command Distribution Through Specialized Handling and Infusion Protocols

By distribution channel, the Hospital Pharmacies segment held the major revenue share in immuno-oncology drugs market. This dominance is structural and unlikely to wane, primarily because the leading immuno-oncology agents are large-molecule biologics requiring intravenous (IV) infusion. The administration of these drugs involves complex logistics, including strictly monitored cold-chain storage (2°C to 8°C) and sterile compounding in USP <797> compliant cleanrooms, infrastructure that retail pharmacies generally lack. Furthermore, the economic model of oncology care in major markets like the U.S. relies heavily on the "buy-and-bill" reimbursement system.

Under this model, hospitals purchase these high-value drugs upfront—often treating the pharmacy as a significant revenue generator for the health system—before billing insurers. Beyond economics, the safety profile of these drugs necessitates hospital administration; the risk of immune-related adverse events (irAEs), such as cytokine release syndrome or pneumonitis, requires immediate access to emergency medical intervention, keeping the dispensing and administration loop tightly closed within the hospital environment.

6,528 Trials Signal Immuno-Oncology Pipeline Explosion

Global research activity currently underscores the robust expansion of the Immuno-oncology drugs market. Data indicates 6,528 oncology clinical trials were projected to complete in 2024, signaling massive throughput. Specific therapeutic focuses are emerging rapidly. Researchers planned 82 new clinical trials for solid tumor treatments to launch in 2024 alone. Stakeholders observe 65 trials targeting Non-Small Cell Lung Cancer (NSCLC) scheduled to commence in the same period. Developers also set 57 new breast cancer clinical trials to begin in 2024, highlighting diverse target indications. Such volume necessitates distinct operational strategies for market entrants.

Scientific dissemination channels reflect this surge in the Immuno-oncology drugs market. Organizers selected 3,000+ abstracts for presentation at the 2024 ASCO Annual Meeting, demonstrating high-yield research output. Merck is conducting 25 registrational studies in early-stage disease settings as of May 2024, pushing the boundaries of curative care. Furthermore, 600+ bispecific antibody candidates are currently in clinical development as of 2024, representing a significant technological shift. These metrics confirm that clinical pipelines are not just active but overflowing with next-generation candidates.

Regulatory Momentum Builds With 60+ Oncology Approvals Granted Within One Year

Regulatory bodies are processing applications at record speeds, acting as a catalyst for the Immuno-oncology drugs market. The FDA issued 60+ oncology drug approvals throughout 2024, validating new mechanisms of action. Activity peaked late in the year, with 15 oncology approvals occurring specifically in the final quarter of 2024. Innovation remains the primary driver of these decisions. Authorities granted approval to 11 first-in-class therapeutics in 2024, offering novel options to patients. October 2024 alone saw 4 new cancer therapies approved by the FDA.

Advanced modalities are receiving particular attention within the Immuno-oncology drugs market. Two first-in-class bispecific antibodies, Zanidatamab and Zenocutuzumab, received accelerated approval in Q4 2024. Earlier in May 2024, the FDA granted approval for the first T-cell engager, tarlatamab, for small cell lung cancer. Historical data supports this trend, as 129 agents were granted accelerated approval for cancer indications between 2013 and 2023, setting a precedent for the intense scrutiny seen in 2024.

Billion Dollar Acquisitions By Vertex and Novartis Drive Immuno-Oncology Drugs Market Consolidation Trends Forward

High-value transactions characterize the current landscape of the Immuno-oncology drugs market. Vertex Pharmaceuticals completed the acquisition of Alpine Immune Sciences for USD 4.9 billion in 2024, securing key assets. Novartis actively strengthened its portfolio through multiple high-profile deals. The pharmaceutical giant signed a licensing deal with Dren Bio potentially valued at USD 3.0 billion in July 2024. Furthermore, Novartis purchased MorphoSys for USD 2.9 billion in 2024 to acquire advanced pipeline candidates.

Consolidation extends beyond these giants in the Immuno-oncology drugs market. AstraZeneca acquired Fusion Pharmaceuticals for USD 2.4 billion in 2024, expanding its radiopharmaceutical capabilities. Similarly, ONO Pharmaceutical acquired Deciphera for USD 2.4 billion in 2024. Johnson & Johnson executed the acquisition of Ambrx Biopharma for USD 2.0 billion in January 2024. These multi-billion dollar capital deployments indicate that established players are aggressively buying innovation rather than solely relying on internal discovery.

Strategic Licensing Deals and High Value Funding Rounds Fuel Commercial Expansion Rapidly

Licensing agreements provide critical capital flow within the Immuno-oncology drugs market. PeptiDream and Novartis signed a peptide-drug conjugate agreement totaling USD 2.89 billion in April 2024. Roche collaborated with Moma Therapeutics in a deal valued at USD 2.07 billion signed in January 2024. Smaller biotech firms also commanded significant valuations. Genmab acquired ProfoundBio for a cash value of USD 1.8 billion in April 2024. Such liquidity ensures continuous development of promising assets.

Emerging players in the Immuno-oncology drugs market are securing substantial resources. Xaira Therapeutics raised USD 1.0 billion in one of the largest Series A financings of 2024. Ipsen entered a licensing agreement with Foreseen Biotechnology potentially valued at USD 1.03 billion in 2024. Additionally, Ipsen signed an exclusive global licensing deal with Sutro Biopharma worth USD 900 million in April 2024. Merck also contributed USD 588 million in an upfront payment to LaNova Medicines in November 2024.

Antibody Drug Conjugate Revenue Soars With Enhertu Leading Global Sales Performance Tables

Commercial performance in the Immuno-oncology drugs market is currently dominated by Antibody-Drug Conjugates (ADCs). Global regulators have approved 17 ADC drugs as of early 2025. Enhertu recorded massive sales revenue of USD 3.75 billion in FY 2024, leading the segment. Padcev followed with sales revenue of USD 1.58 billion in 2024. These figures demonstrate the high reimbursement potential for targeted cytotoxic delivery systems.

Sales data for other key agents confirms the health of the Immuno-oncology drugs market. Trodelvy generated revenue of USD 1.31 billion in 2024. Polivy achieved similar success with sales revenue of USD 1.30 billion in 2024. Even niche products like Elahere reported sales revenue of USD 479 million in 2024. Scientific interest parallels this commercial success, with 30+ distinct ADC abstracts presented at the ASCO 2024 annual meeting. Additionally, 1 new ADC, sacituzumab tirumotecan, received approval in China in 2024.

Pipeline Depth Increases With 600 Bispecific Candidates In Active Development Stages

R&D expenditure proves that stakeholders are betting heavily on the Immuno-oncology drugs market. Bristol Myers Squibb reported an annual R&D expense of USD 11.15 billion for 2024. Keytruda continues to dominate, holding 40 approved indications in the US as of Q2 2024. These indications now cover 17 different tumor types as of 2024. Such broad coverage necessitates continuous clinical evaluation.

Developers are refining their portfolios within the Immuno-oncology drugs market. Merck had 14 Phase 3 trials for Keytruda active in early-stage disease settings between 2022 and 2025. However, strategic discipline is evident; Merck discontinued 2 Phase 3 trials (KEYNOTE-867 and KEYNOTE-630) in August 2024. Emerging data supports continued investment. Immunocore reported 4 patients showed partial tumor responses in a dual-targeting antibody trial presented at ASCO 2024.

Investment Capital And Diagnostic Coding Updates Fortify The Oncology Infrastructure Base Firmly

Financial and administrative structures are evolving to support the Immuno-oncology drugs market. Venture capital remains robust, with 169 funding rounds completed for cancer startups in 2024. These rounds raised a total capital of USD 10.3 billion in 2024. Notable raises include Tubulis securing USD 140 million in Series B financing in March 2024. OnCusp Therapeutics raised USD 100 million in Series A financing in Jan 2024, and Alamar Biosciences raised USD 100 million in Series C financing in Feb 2024.

Reimbursement frameworks are adapting to the Immuno-oncology drugs market. The CPT 2024 code set added 230 new codes, impacting oncology billing. Revisions affected 70 existing codes, while 49 codes were deleted in the 2024 update. Specific advancements include 3 new CPT codes for HIPEC introduced in 2024 and 1 new code for uterine fibroid ablation. Diagnostic precision is improving, with Cleveland Diagnostics raising USD 75 million in Jan 2024 and 7 genes identified in a new methylation panel for lung cancer.

Tailor This Report to Your Specific Business Needs: https://www.astuteanalytica.com/ask-for-customization/immuno-oncology-drugs-market

Immuno-Oncology Drugs Market Major Players:

Key Market Segmentation:

By Treatment Type

By Disease Type

By Distribution Channel

By Region

Need a Detailed Walkthrough of the Report? Request a Live Session: https://www.astuteanalytica.com/report-walkthrough/immuno-oncology-drugs-market

About Astute Analytica

Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements.

With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace.

Contact Us:

Astute Analytica

Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)

For Sales Enquiries: sales@astuteanalytica.com

Website: https://www.astuteanalytica.com/

Follow us on: LinkedIn | Twitter | YouTube